^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Breast Cancer
    Drug:toremifene (Selective estrogen receptor modulator)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    05/12/2017
    Excerpt:
    FARESTON® is an estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors.
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Excerpt:
    First line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients.